At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05352321N/ARecruitingUpdate OverdueUpdated 48mo ago · Completion was 13mo agoMulticenter Randomized Controlled Trial of Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
In Brief
A clinical study evaluating Gemcitabine, Cisplatin, and 3 other interventions for Nasopharyngeal Carcinoma. Currently recruiting, targeting 264 participants across 2 sites.
Signals
Detailed Summary
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.
Study Details
Timeline
Interventions
for induction chemotherapy
for induction and concurrent chemotherapy
in active comparator arm
in experimental arm
in experimental arm